Rallybio partners with Johnson & Johnson to develop therapeutic solutions for FNAIT, receiving $6.6m investment and potential milestone payments.
Rallybio Corporation partners with Johnson & Johnson to advance therapeutic solutions for pregnant individuals at risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Rallybio is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody. The collaboration includes an equity investment of $6.6m from Johnson & Johnson Innovation - JJDC, Inc. Rallybio will receive an upfront $500k payment and potential milestone payments of up to $3.7m.
April 10, 2024
3 Articles